United States

Drug Pricing

Transenterix won't compete head-on with Intuitive Surgical: CEO

Transenterix Inc's chief executive played down on Tuesday the threat posed by his company's surgical robotic system to market leader Intuitive Surgical Inc, saying he did not expect the two to compete head on.

Published on Oct 23, 2015

This clip features Professor Meredith Rosenthal, Dr. Aaron Kesselheim and Dr. Steven Pearson, who spoke during Drug Pricing: Public Health Implications on Friday, October 23, 2015. The event was presented in collaboration with Reuters and in association with Harvard Health Publications.

More headlines

Regeneron-Sanofi drug succeeds mid-stage study

Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat inflammation in the esophagus, mainly caused by food allergies, met the main goal of a mid-stage study.

Oct 16 2017

U.S. judge in Texas invalidates Allergan patents on Restasis

A U.S. judge on Monday invalidated patents on Allergan Plc's dry-eye medicine Restasis on grounds that the patents cover ideas that are obvious, sending shares of the pharmaceutical company down 3.5 percent.

Oct 16 2017

FDA panel backs gene therapy for rare form of blindness

Spark Therapeutics Inc's experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded on Thursday, paving the way for the first U.S. gene therapy for an inherited disease.

Oct 12 2017

Trump names Eric Hargan as acting Health Secretary

President Donald Trump has appointed Eric Hargan as acting Secretary of Health and Human Services (HHS), the White House said on Tuesday.

Oct 10 2017

Food and drug chief Gottlieb skirts health secretary talk, says most effective at FDA

U.S. Food and Drug Administration Commissioner Scott Gottlieb, considered a potential successor to recently departed Health and Human Services Secretary Tom Price, said on Tuesday he believed he could best serve the Trump administration in his current role.

Oct 10 2017

Spark gene therapy improves vision, at least in short term: FDA

Spark Therapeutics Inc's experimental gene therapy for a rare inherited form of blindness improves vision, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration.

Oct 10 2017

China to accept overseas trial data in bid to speed up drug approvals

SHANGHAI China said it plans to accept data from overseas clinical trials to speed up approvals of drugs, a potential boon for international drugmakers as well as patients who often face lengthy delays for new medicines to reach the market.

Oct 09 2017

California governor signs drug pricing transparency law

California Governor Jerry Brown on Monday signed state legislation requiring drug companies to report certain price hikes for prescription medicines in a move that could set a model for other states to follow.

Oct 09 2017

Flexion's knee pain drug gets FDA nod, shares hit life high

Flexion Therapeutics Inc said its injectable drug to treat osteoarthritis-related knee pain was approved by the U.S. Food and Drug Administration, sending the drug developer's shares soaring to a record high in regular trading on Friday.

Oct 06 2017

Reuters Collaborations with The Forum at Harvard T.H. Chan School of Public Health


Health News


McDonald's South Korea office raided in burger probe: reports

SEOUL South Korean investigators raided the Seoul office of McDonald's Corp on Wednesday, following a series of complaints that children fell ill after eating hamburger patties alleged to have been undercooked, Yonhap News Agency and other media said.


Allergan ruling casts doubt on tribal patent strategy

A U.S. judge’s ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.


Johnson & Johnson wins reversal of $72 million verdict over talc cancer risks

Johnson & Johnson on Tuesday won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company's talc-based products like Johnson's Baby Powder.

Astra and Merck win speedy review for Lynparza in breast cancer

LONDON U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018.


Trump's drug czar nominee withdraws from consideration

WASHINGTON The U.S. lawmaker who was President Donald Trump's pick for drug czar withdrew on Tuesday after a report he spearheaded a bill that hurt the government's ability to crack down on opioid makers flooding the market with the addictive painkillers. | Video